Carboxylesterase 1 in Alcoholic Liver Disease
酒精性肝病中的羧酸酯酶 1
基本信息
- 批准号:9196434
- 负责人:
- 金额:$ 21.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-10 至 2018-07-31
- 项目状态:已结题
- 来源:
- 关键词:4 hydroxynonenal5&apos-AMP-activated protein kinaseADD-1 proteinAcetaldehydeAcetyl-CoA CarboxylaseAdipose tissueAlcohol abuseAlcohol consumptionAlcoholic Fatty LiverAlcoholic HepatitisAlcoholic Liver DiseasesAlcoholsBile AcidsCellsCirrhosisDataDeacetylaseDevelopmentEnergy MetabolismEnzymesEthanolEthanol MetabolismExhibitsExposure toFatty LiverGenetic TranscriptionGlucoseHealthHeartHepaticHigh Fat DietHumanHydrolysisIncidenceInflammationIntestinesInvestigationKidneyKnockout MiceLeadLipidsLipolysisLipopolysaccharidesLiverLiver CirrhosisLiver diseasesMalondialdehydeMicrotubulesMitochondriaMusNADHNonesterified Fatty AcidsNuclear Hormone ReceptorsPPAR alphaPalmitic AcidsPancreasPathogenesisPatientsPharmaceutical PreparationsPlayPreventionPrimary carcinoma of the liver cellsReactive Oxygen SpeciesRegulationRoleSRE-1 binding proteinSteatohepatitisTestingTherapeuticTransgenic MiceTriglyceridesVery low density lipoproteinWild Type MouseXenobioticsalcohol abstinencebasecarboxylesterasediabeticdrug metabolismfeedingglucose metabolismhepatic nuclear factor 1hepatocyte nuclear factorimprovedinsightinsulin sensitivitylipid biosynthesislipid metabolismliver inflammationliver injurymacrophagemetabolomenoveloverexpressionproblem drinkerresponsesterol esterasetherapeutic targettranscriptometreatment strategyuptakewestern diet
项目摘要
Project Summary
Project Summary: Alcoholic liver disease (ALD) is a major cause of advanced liver disease worldwide. ALD
consists of a spectrum of liver disorders, ranging from simple steatosis to more severe forms of liver injury,
including alcoholic steatohepatitis, cirrhosis and hepatocellular carcinoma. To reduce the incidence of ALD,
abstinence from alcohol abuse is critical for prevention of the development of ALD. From the therapeutic
standpoint, however, little progress has been made towards the treatment of ALD over the past 40 years.
Carboxylesterase 1 (CES1) is a drug-metabolizing enzyme that is highly expressed in the liver and to a lesser
extent in intestine, macrophages, heart, pancreas, kidney and adipose tissue. CES1 possesses both
triglyceride (TG) and cholesterol ester hydrolase activity. We have previously shown that CES1 inhibits
hepatic TG accumulation by regulating TG hydrolysis, FAO and lipogenesis. Gain of hepatic CES1 function
is also shown to improve insulin sensitivity in diabetic or high fat diet-fed mice. Our preliminary data show
that Ces1 -/- mice display aggravated alcohol-induced liver injury and inflammation while over-expression of
CES1 inhibits inflammation and ethanol-induced TG accumulation. Based on these observations, we
hypothesize that hepatic CES1 plays a protective role in the pathogenesis of ALD. To test this hypothesis,
we will use liver-specific Ces1 knockout or transgenic mice to investigate the role of hepatic CES1 in ALD as
well as the underlying mechanism. In addition, we will also investigate the regulation of CES1 by ethanol.
Completion of the proposed studies will help elucidate the role of hepatic CES1 in the pathogenesis of ALD
and may lead to identification of CES1 as an attractive target for treatment of ALD.
项目摘要
项目概述:酒精性肝病(ALD)是全球晚期肝病的主要原因。ALD
包括一系列肝脏疾病,从简单的脂肪变性到更严重的肝损伤,
包括酒精性脂肪性肝炎、肝硬化和肝细胞癌。为了减少酒精性肝脏病的发病率,
戒酒对于预防ALD的发展至关重要。从治疗
然而,在过去的40年里,ALD的治疗进展甚微。
羧酸酯酶1(CES 1)是一种药物代谢酶,在肝脏中高度表达,
肠、巨噬细胞、心脏、胰腺、肾脏和脂肪组织中的程度。CES 1同时具有
甘油三酯(TG)和胆固醇酯水解酶活性。我们之前已经证明CES 1抑制了
通过调节TG水解、FAO和脂肪生成来实现肝脏TG蓄积。肝CES 1功能获得
还显示出改善糖尿病或高脂肪饮食喂养的小鼠的胰岛素敏感性。我们的初步数据显示
Ces 1-/-小鼠表现出加重的酒精诱导的肝损伤和炎症,同时过度表达
CES 1抑制炎症和乙醇诱导的TG积累。根据这些观察,我们
推测肝CES 1在ALD的发病机制中起保护作用。为了验证这个假设,
我们将使用肝脏特异性Ces 1基因敲除或转基因小鼠来研究肝脏Ces 1在ALD中的作用,
以及潜在的机制。此外,我们还将研究乙醇对CES 1的调控。
这些研究的完成将有助于阐明肝脏CES 1在ALD发病机制中的作用
并且可能导致将CES 1鉴定为治疗ALD的有吸引力的靶标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yanqiao Zhang其他文献
Yanqiao Zhang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yanqiao Zhang', 18)}}的其他基金
Hepatic FOXA3 Links NAFLD to Atherosclerosis
肝脏 FOXA3 将 NAFLD 与动脉粥样硬化联系起来
- 批准号:
10364733 - 财政年份:2019
- 资助金额:
$ 21.79万 - 项目类别:
Hepatic FOXA3 Links NAFLD to Atherosclerosis
肝脏 FOXA3 将 NAFLD 与动脉粥样硬化联系起来
- 批准号:
9891056 - 财政年份:2019
- 资助金额:
$ 21.79万 - 项目类别:
Identification of Novel Genes/Pathways That Regulate Atherogenesis
调节动脉粥样硬化形成的新基因/途径的鉴定
- 批准号:
10199006 - 财政年份:2018
- 资助金额:
$ 21.79万 - 项目类别:
Mechanisms Underlying the Pathogenesis of Non-alcoholic Fatty Liver Disease
非酒精性脂肪肝发病机制
- 批准号:
10594713 - 财政年份:2015
- 资助金额:
$ 21.79万 - 项目类别:
Mechanisms Underlying the Pathogenesis of Non-alcoholic Fatty Liver Disease
非酒精性脂肪肝发病机制
- 批准号:
9310238 - 财政年份:2015
- 资助金额:
$ 21.79万 - 项目类别:
相似国自然基金
晚期妊娠维持和抑制早产中cAMP信号活化PR的作用机制研究
- 批准号:81300507
- 批准年份:2013
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
相似海外基金
P1082 - Revealing Mercer 5's Pulsar Population with Parkes
P1082 - 揭秘默瑟 5
- 批准号:
Local : csiro:P1082 - 财政年份:
- 资助金额:
$ 21.79万 - 项目类别:














{{item.name}}会员




